96 related articles for article (PubMed ID: 27993946)
41. Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients.
Park HS; Lee JK; Kim DW; Kulig K; Kim TM; Lee SH; Jeon YK; Chung DH; Heo DS
Lung Cancer; 2012 Aug; 77(2):288-92. PubMed ID: 22465695
[TBL] [Abstract][Full Text] [Related]
42. Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH.
Yi ES; Boland JM; Maleszewski JJ; Roden AC; Oliveira AM; Aubry MC; Erickson-Johnson MR; Caron BL; Li Y; Tang H; Stoddard S; Wampfler J; Kulig K; Yang P
J Thorac Oncol; 2011 Mar; 6(3):459-65. PubMed ID: 21278610
[TBL] [Abstract][Full Text] [Related]
43. Novel glioblastoma markers with diagnostic and prognostic value identified through transcriptome analysis.
Reddy SP; Britto R; Vinnakota K; Aparna H; Sreepathi HK; Thota B; Kumari A; Shilpa BM; Vrinda M; Umesh S; Samuel C; Shetty M; Tandon A; Pandey P; Hegde S; Hegde AS; Balasubramaniam A; Chandramouli BA; Santosh V; Kondaiah P; Somasundaram K; Rao MR
Clin Cancer Res; 2008 May; 14(10):2978-87. PubMed ID: 18483363
[TBL] [Abstract][Full Text] [Related]
44. KPNA2 predicts long term survival in patients with anaplastic oligoastrocytomas.
Gousias K; Niehusmann P; Gielen G; Simon M; Boström J
J Clin Neurosci; 2014 Oct; 21(10):1719-24. PubMed ID: 24929863
[TBL] [Abstract][Full Text] [Related]
45. Nuclear Protein Phosphatase 1 α (PP1A) Expression is Associated with Poor Prognosis in p53 Expressing Glioblastomas.
Shastry AH; Thota B; Srividya MR; Arivazhagan A; Santosh V
Pathol Oncol Res; 2016 Apr; 22(2):287-92. PubMed ID: 26253838
[TBL] [Abstract][Full Text] [Related]
46. IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme.
Kalkan R; Atli Eİ; Özdemir M; Çiftçi E; Aydin HE; Artan S; Arslantaş A
Gene; 2015 Jan; 554(1):81-6. PubMed ID: 25455102
[TBL] [Abstract][Full Text] [Related]
47. ALK status testing in non-small-cell lung carcinoma by FISH on ThinPrep slides with cytology material.
Minca EC; Lanigan CP; Reynolds JP; Wang Z; Ma PC; Cicenia J; Almeida FA; Pennell NA; Tubbs RR
J Thorac Oncol; 2014 Apr; 9(4):464-8. PubMed ID: 24736067
[TBL] [Abstract][Full Text] [Related]
48. IDH1 mutations in diffusely infiltrating astrocytomas: grade specificity, association with protein expression, and clinical relevance.
Thota B; Shukla SK; Srividya MR; Shwetha SD; Arivazhagan A; Thennarasu K; Chickabasaviah YT; Hegde AS; Chandramouli BA; Somasundaram K; Santosh V
Am J Clin Pathol; 2012 Aug; 138(2):177-84. PubMed ID: 22904127
[TBL] [Abstract][Full Text] [Related]
49. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas.
Boland JM; Erdogan S; Vasmatzis G; Yang P; Tillmans LS; Johnson MR; Wang X; Peterson LM; Halling KC; Oliveira AM; Aubry MC; Yi ES
Hum Pathol; 2009 Aug; 40(8):1152-8. PubMed ID: 19386350
[TBL] [Abstract][Full Text] [Related]
50. Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening.
Lee J; Kim HC; Hong JY; Wang K; Kim SY; Jang J; Kim ST; Park JO; Lim HY; Kang WK; Park YS; Lee J; Lee WY; Park YA; Huh JW; Yun SH; Do IG; Kim SH; Balasubramanian S; Stephens PJ; Ross JS; Li GG; Hornby Z; Ali SM; Miller VA; Kim KM; Ou SH
Oncotarget; 2015 Sep; 6(27):24320-32. PubMed ID: 26172300
[TBL] [Abstract][Full Text] [Related]
51. Immunohistochemistry as a screening tool for ALK rearrangement in NSCLC: evaluation of five different ALK antibody clones and ALK FISH.
Hutarew G; Hauser-Kronberger C; Strasser F; Llenos IC; Dietze O
Histopathology; 2014 Sep; 65(3):398-407. PubMed ID: 24612196
[TBL] [Abstract][Full Text] [Related]
52. Evaluation of tyrosine kinase receptors in brain metastases of clear cell renal cell carcinoma reveals cMet as a negative prognostic factor.
Schiefer AI; Mesteri I; Berghoff AS; Haitel A; Schmidinger M; Preusser M; Birner P
Histopathology; 2015 Dec; 67(6):799-805. PubMed ID: 25847631
[TBL] [Abstract][Full Text] [Related]
53. Is ALK-gene rearrangement overlooked in primary gastrointestinal T-cell lymphomas? About two cases.
Mneimneh WS; Vyas SG; Cheng L; Cummings OW; Czader M
Pathol Int; 2015 Dec; 65(12):666-70. PubMed ID: 26531107
[TBL] [Abstract][Full Text] [Related]
54. ALK-FISH borderline cases in non-small cell lung cancer: Implications for diagnostics and clinical decision making.
von Laffert M; Stenzinger A; Hummel M; Weichert W; Lenze D; Warth A; Penzel R; Herbst H; Kellner U; Jurmeister P; Schirmacher P; Dietel M; Klauschen F
Lung Cancer; 2015 Dec; 90(3):465-71. PubMed ID: 26547803
[TBL] [Abstract][Full Text] [Related]
55. EGFR and KRAS Mutations in ALK-Positive Lung Adenocarcinomas: Biological and Clinical Effect.
Sahnane N; Frattini M; Bernasconi B; Zappa F; Schiavone G; Wannesson L; Antonelli P; Balzarini P; Sessa F; Mazzucchelli L; Tibiletti MG; Martin V
Clin Lung Cancer; 2016 Jan; 17(1):56-61. PubMed ID: 26381283
[TBL] [Abstract][Full Text] [Related]
56. Screening for ALK in non-small cell lung carcinomas: 5A4 and D5F3 antibodies perform equally well, but combined use with FISH is recommended.
Savic S; Diebold J; Zimmermann AK; Jochum W; Baschiera B; Grieshaber S; Tornillo L; Bisig B; Kerr K; Bubendorf L
Lung Cancer; 2015 Aug; 89(2):104-9. PubMed ID: 26056079
[TBL] [Abstract][Full Text] [Related]
57. Expression of Anaplastic Lymphoma Kinase (ALK) in glioma and possible clinical correlations. A retrospective institutional study.
Azab MA
Cancer Treat Res Commun; 2023; 36():100703. PubMed ID: 37271069
[TBL] [Abstract][Full Text] [Related]
58. Prognostic role of ALK-1 and h-TERT expression in glioblastoma multiforme: correlation with ALK gene alterations.
Elsers D; Temerik DF; Attia AM; Hadia A; Hussien MT
J Pathol Transl Med; 2021 May; 55(3):212-224. PubMed ID: 33966367
[TBL] [Abstract][Full Text] [Related]
59. Receptor Tyrosine Kinase Signaling and Targeting in Glioblastoma Multiforme.
Tilak M; Holborn J; New LA; Lalonde J; Jones N
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33673213
[TBL] [Abstract][Full Text] [Related]
60. MET immunolabelling is a useful predictive tool for MET gene amplification in glioblastoma.
Burel-Vandenbos F; Ngo-Mai M; Dadone B; Di Mauro I; Gimet S; Saada-Bouzid E; Bourg V; Almairac F; Fontaine D; Virolle T; Pedeutour F
Neuropathol Appl Neurobiol; 2017 Apr; 43(3):252-266. PubMed ID: 26946354
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
